Skip to main content

tisagenlecleucel (Kymriah®)

 

Status: Excluded due to NICE appraisal

Product meets AWMSG exclusion criteria due to NICE appraisal TA975: Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under

Medicine details

Medicine name tisagenlecleucel (Kymriah®)
Formulation dispersion for infusion
Reference number 2668
Indication

Treatment of paediatric and young adult patients up to 25 years of age with B‑cell acute lymphoblastic leukaemia that is refractory, in relapse post‑transplant or in second or later relapse

Company Novartis Pharmaceuticals UK Ltd
BNF chapter Malignant disease & immunosuppression
Submission type N/A
Status Excluded due to NICE appraisal
Date of issue 09/04/2024
NICE guidance

TA975: Tisagenlecleucel for treating relapsed or refractory B-cell acute lymphoblastic leukaemia in people 25 years and under

Follow AWTTC: